Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Shares Outstanding (2016 - 2023)

Endonovo Therapeutics has reported Shares Outstanding over the past 13 years, most recently at $318.8 million for Q3 2023.

  • Quarterly results put Shares Outstanding at $318.8 million for Q3 2023, up 1274906.39% from a year ago — trailing twelve months through Sep 2023 was $318.8 million (up 1274906.39% YoY), and the annual figure for FY2022 was $213.2 million, up 852810.15%.
  • Shares Outstanding for Q3 2023 was $738.0 at Endonovo Therapeutics, down from $289.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding for ENDV hit a ceiling of $289.2 million in Q2 2023 and a floor of $305.0 in Q3 2020.
  • Median Shares Outstanding over the past 5 years was $25000.0 (2019), compared with a mean of $29.2 million.
  • Biggest five-year swings in Shares Outstanding: plummeted 100.0% in 2021 and later soared 1274906.39% in 2023.
  • Endonovo Therapeutics' Shares Outstanding stood at $600.0 in 2019, then soared by 4066.67% to $25000.0 in 2020, then changed by 0.0% to $25000.0 in 2021, then soared by 852810.15% to $213.2 million in 2022, then soared by 49.49% to $318.8 million in 2023.
  • The last three reported values for Shares Outstanding were $318.8 million (Q3 2023), $25000.0 (Q2 2023), and $25000.0 (Q1 2023) per Business Quant data.